AstraZeneca vs Uber: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and Uber side by side

1. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

2. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

3. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

4. 2000AstraZeneca

   Nexium Launch Replaces Prilosec

   AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

5. 2006AstraZeneca

   Acquisition of Cambridge Antibody Technology

   AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

6. 2007AstraZeneca

   Acquisition of MedImmune for $15.6 Billion

   AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

7. 2009Uber

   UberCab idea takes shape

   Garrett Camp and Travis Kalanick developed the Uber idea after discussing the difficulty of getting a reliable ride in Paris and San Francisco.

8. 2010Uber

   San Francisco service launch

   Uber launched service in San Francisco in 2010, proving that riders would pay for visible arrival times, stored payment, and digital receipts.

9. 2012AstraZeneca

   Pascal Soriot Appointed CEO

   Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

10. 2012Uber

    UberX expands the addressable market

    UberX brought lower-priced rides from personal vehicles into the product mix. That shift moved the company beyond premium black cars, increased driver supply, and opened the larger regulatory debate over licensing, insurance, and worker classification.

11. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

12. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

13. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

14. 2016Uber

    China exit through Didi deal

    Uber exited China by selling its local operation to Didi Chuxing after an expensive subsidy fight. The retreat showed that local payments, regulation, mapping, and distribution could outweigh global capital and brand recognition.

15. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

16. 2017Uber

    Dara Khosrowshahi becomes CEO

    Dara Khosrowshahi replaced Travis Kalanick as CEO after a year of cultural, legal, and regulatory crises. The transition mattered because Uber needed a more credible operating and governance model before entering public markets.

17. 2019Uber

    Uber becomes a public company

    Uber completed its initial public offering in May 2019 and later reported roughly $8.0 billion in net IPO proceeds. The listing forced the company to explain its economics to public investors and shifted attention from geographic expansion to profitability.

18. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

19. 2020Uber

    Postmates acquisition strengthens U.S. Delivery

    Uber agreed to acquire Postmates for approximately $2.65 billion in an all-stock transaction. The deal added U.S. Delivery density, local merchant relationships, and delivery-as-a-service capabilities as Eats became more important during the pandemic.

20. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

21. 2021Uber

    Uber One launches

    Uber One launched as a paid membership connecting rides, delivery, and groceries. The product mattered because it gave frequent users a reason to keep more transactions inside one account instead of switching between single-category rivals.

22. 2021Uber

    Uber Freight agrees to buy Transplace

    Uber Freight agreed to acquire Transplace for approximately $2.25 billion. The deal moved Freight deeper into managed transportation and shipper software, a different business from consumer rides but tied to the same broader logistics ambition.

23. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

24. 2023Uber

    Waymo partnership brings autonomous rides to Uber

    Waymo and Uber announced a multi-year partnership to make the Waymo Driver available through the Uber platform, starting in Phoenix. The deal showed Uber's post-ATG autonomy strategy: partner with vehicle specialists while keeping the marketplace relationship.

25. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

26. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

27. 2024Uber

    $44.0 billion revenue year

    FY2024 revenue reached $44.0 billion, up from $37.3 billion in FY2023. The result showed that mobility had recovered after the pandemic while delivery remained a larger and more durable part of the business.

28. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

29. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

30. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

31. 2025Uber

    $52.0 billion revenue and $193.5 billion gross bookings

    FY2025 revenue reached $52.0 billion, gross bookings reached $193.5 billion, and annual trips rose to 13.6 billion. The milestone mattered because it showed growth alongside GAAP operating income, adjusted EBITDA, and free cash flow at significant scale.

32. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

33. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

34. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

35. 2026Uber

    $14.8 billion Delivery Hero offer and 3,300-role restructuring

    Uber offered €41.50 per share for Delivery Hero in July 2026 and launched the tender in September after Delivery Hero's boards backed it. The same month it announced about 3,300 corporate job cuts to remove management layers.

Acquisitions

Questions about AstraZeneca vs Uber